# Amylyx Pharmaceuticals, Inc. (AMLX) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from Amylyx Pharmaceuticals, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/AMLX/mda/fy2025/): filed 2026-03-03; accession 0001193125-26-086645 (https://www.sec.gov/Archives/edgar/data/1658551/000119312526086645/amlx-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/AMLX/mda/fy2024/): filed 2025-03-04; accession 0000950170-25-031309 (https://www.sec.gov/Archives/edgar/data/1658551/000095017025031309/amlx-20241231.htm)
- [FY 2023 MD&A](/company/AMLX/mda/fy2023/): filed 2024-02-22; accession 0000950170-24-018447 (https://www.sec.gov/Archives/edgar/data/1658551/000095017024018447/amlx-20231231.htm)
- [FY 2022 MD&A](/company/AMLX/mda/fy2022/): filed 2023-03-13; accession 0000950170-23-007609 (https://www.sec.gov/Archives/edgar/data/1658551/000095017023007609/amlx-20221231.htm)
- [FY 2021 MD&A](/company/AMLX/mda/fy2021/): filed 2022-03-31; accession 0000950170-22-005157 (https://www.sec.gov/Archives/edgar/data/1658551/000095017022005157/almx-10-2021.htm)

Back to /company/AMLX/